Anika Therapeutics received FDA 510(k) clearance to market a resorbable, injectable hyaluronic acid-based bone void filler, SCS 17-01.
As we noted in coverage of ANIK’s 3Q17 revenue, the company had submitted the application within 3Q17.
Orthopaedic surgeon John Tierney, D.O., who has worked with the product, remarked, “Anika’s 510(k) clearance allows for the marketing of one of only a handful of bone graft substitutes that can be administered in a minimally invasive manner. It offers physicians an additional option for treating bone defects or injuries, without the need for expensive and high risk surgeries, while also reducing the operating room time spent on each case.”
Sources: Anika Therapeutics, Inc.; FDA.gov; ORTHOWORLD Inc.
Anika Therapeutics received FDA 510(k) clearance to market a resorbable, injectable hyaluronic acid-based bone void filler, SCS 17-01.
As we noted in coverage of ANIK's 3Q17 revenue, the company had submitted the application within 3Q17.
Orthopaedic surgeon John Tierney, D.O., who has worked with the product, remarked, "Anika’s 510(k)...
Anika Therapeutics received FDA 510(k) clearance to market a resorbable, injectable hyaluronic acid-based bone void filler, SCS 17-01.
As we noted in coverage of ANIK’s 3Q17 revenue, the company had submitted the application within 3Q17.
Orthopaedic surgeon John Tierney, D.O., who has worked with the product, remarked, “Anika’s 510(k) clearance allows for the marketing of one of only a handful of bone graft substitutes that can be administered in a minimally invasive manner. It offers physicians an additional option for treating bone defects or injuries, without the need for expensive and high risk surgeries, while also reducing the operating room time spent on each case.”
Sources: Anika Therapeutics, Inc.; FDA.gov; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.